All In Biotech

Drug Trial Radar · NCT01020383

Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro®) Over a Period of 24 Hours

Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 364 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

364

Actual

Start

Sep 2009

Primary completion

Apr 2011

Study completion Mar 2012

Sponsor

Lead sponsor
Ablynx, a Sanofi companyIndustry
Sponsor type
Industry
First posted
Nov 24, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients. Patients will receive standard treatment with acetylsalicylic acid (ASA) plus clopidogrel and heparin. Eligible patients will be randomly assigned to receive open-label study treatment with either ALX-0081 or ReoPro®. Patients will be stratified according to PCI type (elective or ad-hoc) and stent type (bare metal stent or drug eluting stent).

Conditions

  • Unstable Angina
  • Non ST Segment Elevation Myocardial Infarction (NSTEMI)
  • Stable Angina (Associated With High Risk PCI)

Interventions

  • ALX-0081Drug

    4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg

  • ReoPro®Drug

    0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of bleeding classified by the following criteria: TIMI major bleeding events, TIMI minor bleeding events, bleeding events requiring medical attention, defined as TIMI minimal bleeding eventsTime frame: 30 days

Locations

39 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Graz, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Aalst, Belgium

  • Site not named

    Charleroi, Belgium

  • Site not named

    Genk, Belgium

  • Site not named

    Jette, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Yvoir, Belgium

  • Site not named

    Brno, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Ústí nad Labem, Czechia

  • Site not named

    Bad Nauheim, Germany

  • Site not named

    Coburg, Germany

  • Site not named

    Dortmund, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Limburg, Germany

  • Site not named

    Oldenburg, Germany

  • Site not named

    Rostock, Germany

  • Site not named

    Ashkelion, Israel

  • Site not named

    Haifa, Israel

  • Site not named

    Jerusalem, Israel

  • Site not named

    Rehovot, Israel

  • Site not named

    Tel HaShomer, Israel

  • Site not named

    Bielsko-Biala, Poland

  • Site not named

    Dąbrowa Górnicza, Poland

  • Site not named

    Gdynia, Poland

  • Site not named

    Grodzisk Mazowiecki, Poland

  • Site not named

    Katowice, Poland

  • Site not named

    Kędzierzyn, Poland

  • Site not named

    Kościerzyna, Poland

  • Site not named

    Krakow, Poland

  • Site not named

    Lódz, Poland

  • Site not named

    Poznan, Poland

  • Site not named

    Torun, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Wroclaw, Poland

  • Site not named

    Lausanne, Switzerland

  • Site not named

    Lugano, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.